Results 91 to 100 of about 27,546 (256)

ANALISIS DESKRIPTIF JUMLAH EOSINOFIL MUKOSA KONJUNGTIVA DAN DERAJAT KONJUNGTIVITIS ALERGI BERDASARKAN 5-5-5 EXACERBATION GRADING SCALE [PDF]

open access: yes, 2016
Hanani Kusumasari, G0012088, 2015. Analisis Deskriptif Jumlah Eosinofil Mukosa Konjungtiva dan Derajat Konjungtivitis Alergi Berdasarkan 5-5-5 Exacerbation Grading Scale. Skripsi.
Kusumasari, Hanani
core  

Impression cytology in vernal conjunctivitis [PDF]

open access: yes, 2004
PURPOSE: To study conjunctival surface changes caused by chronic inflammation in vernal keratoconjunctivitis using impression cytology. METHODS: Samples of conjunctival epithelium were collected from 30 patients with vernal keratoconjunctivitis and 30 ...
Barros, Jeison de Nadai   +3 more
core   +3 more sources

Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open‐label extension study

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
This study evaluated long‐term safety and efficacy in patients with moderate‐to‐severe atopic dermatitis. Patients with and without previous nemolizumab experience received nemolizumab 30 mg Q4W plus TCS/TCI. Nemolizumab was well‐tolerated through 104 weeks with clinically meaningful improvements in disease signs and symptoms.
Matthias Augustin   +24 more
wiley   +1 more source

Immunopathology of Allergic Conjunctivitis

open access: yesEuropean Medical Journal, 2018
Allergic conjunctivitis is predominantly an immunoglobulin E-mediated hypersensitivity reaction to environmental allergens. Allergic diseases affect >30% of the world’s population, of which 40% report associated ocular manifestations. Cellular and soluble mediators play a major role in the pathophysiology of allergic conjunctivitis.
DeGaulle I. Chigbu, Bhawanjot K. Minhas
openaire   +2 more sources

Long‐term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236‐week, Phase 3 trial results

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
In this Phase III study, secukinumab demonstrated sustained efficacy and a favourable safety profile in paediatric patients with chronic severe plaque psoriasis over a treatment period of 236 weeks. Abstract Background Plaque psoriasis, a chronic inflammatory disease, affects up to 2.1% of the global paediatric population.
Andrzej Kaszuba   +11 more
wiley   +1 more source

Health-related quality of life in food hypersensitive schoolchildren and their families: parents' perceptions [PDF]

open access: yes, 2006
Background About 20% of schoolchildren and adolescents in Sweden suffer from perceived food hypersensitivity (e.g. allergy or intolerance). Our knowledge of how child food hypersensitivity affects parents HRQL and what aspects of the hypersensitivity ...
Birgitta Marklund   +50 more
core   +2 more sources

Allergic conjunctivitis.

open access: yesCommunity eye health
Citation: 'allergic conjunctivitis' in the IUPAC Compendium of Chemical Terminology, 5th ed.; International Union of Pure and Applied Chemistry; 2025. Online version 5.0.0, 2025. 10.1351/goldbook.13037 • License: The IUPAC Gold Book is licensed under Creative Commons Attribution-ShareAlike CC BY-SA 4.0 International for individual terms ...
Varsha M, Rathi, Somasheila I, Murthy
openaire   +3 more sources

Treatment of patients with allergic conjunctivitis: experience of an outpatient ophthalmologist [PDF]

open access: yesКлиническая офтальмология
G.A. Azamatova1, G.R. Altynbaeva2 1Bashkir State Medical University, Ufa, Russian Federation 2City Clinical Hospital No. 5 of the city of Ufa, Ufa, Russian Federation Allergic conjunctivitis (AC) is one of the common eye diseases.
G.A. Azamatova, G.R. Altynbayeva
doaj  

Frequency of Sensitization to Aeroallergens in Patients with Seasonal and Perennial Allergic Conjunctivitis

open access: yesRevista Alergia México, 2014
Background: Allergic conjunctivitis is an in ammatory disease which involves the conjunctiva, its physiopathology is a type I hypersensitivity (IgE mediated). It is related to the sensitization to indoors and out- doors aeroallergens.
Guillermina Cortés-Morales   +3 more
doaj   +1 more source

Efficacy of up to 4 years of tralokinumab in adults with moderate‐to‐severe atopic dermatitis

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
AD is a relapsing and remitting skin disease often requiring long‐term treatment. We assessed the long‐term efficacy of tralokinumab in adults with moderate‐to‐severe AD consistently treated for up to 4 years. Treatment with tralokinumab plus optional TCS/TCI provided substantial improvements in AD signs and symptoms, and these improvements were ...
Melinda Gooderham   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy